{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:23:02Z","timestamp":1756902182136,"version":"3.44.0"},"reference-count":36,"publisher":"The Pediatric Pharmacy Association","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>Mitogen-activated extracellular kinase inhibitors, including trametinib and selumetinib, are increasingly used to treat pediatric low-grade gliomas. Trametinib, while administered orally and with minimal myelosuppression, is reported to cause rash, diarrhea, and fatigue. Selumetinib has been associated with skin irritation, diarrhea, and musculoskeletal pain. This case report describes an 8-month-old male with a low-grade glioma (LGG) that progressed 6 months post-chemotherapy and was started on trametinib due to its liquid formulation and minimal side effect profile. However, the patient developed severe diarrhea, abdominal pain, neck pain, rigidity, and decreased stamina. These symptoms necessitated discontinuation of trametinib, after which all symptoms resolved within a week. This case highlights the first reported instance of trametinib-induced myalgia and rigidity in a pediatric patient receiving trametinib therapy for a LGG. Clinicians should consider these rare but significant adverse effects when choosing an antineoplastic therapy for the treatment of progressive LGG.<\/jats:p>","DOI":"10.5863\/jppt-24-00002","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T19:46:09Z","timestamp":1755114369000},"page":"515-519","source":"Crossref","is-referenced-by-count":0,"title":["Myalgia and Rigidity as Adverse Effects of Trametinib Therapy"],"prefix":"10.5863","volume":"30","author":[{"given":"Charles J","family":"Weeks","sequence":"first","affiliation":[{"name":"School of Medicine (CJW, RV, DT, ABS), Department of Pharmacy (VF), Department of Internal Medicine (MS), and Department of Pediatrics (CM) of the Medical College of Georgia at Augusta University, Augusta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Frame","sequence":"additional","affiliation":[{"name":"School of Medicine (CJW, RV, DT, ABS), Department of Pharmacy (VF), Department of Internal Medicine (MS), and Department of Pediatrics (CM) of the Medical College of Georgia at Augusta University, Augusta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohan","family":"Vuppala","sequence":"additional","affiliation":[{"name":"School of Medicine (CJW, RV, DT, ABS), Department of Pharmacy (VF), Department of Internal Medicine (MS), and Department of Pediatrics (CM) of the Medical College of Georgia at Augusta University, Augusta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Thomas","sequence":"additional","affiliation":[{"name":"School of Medicine (CJW, RV, DT, ABS), Department of Pharmacy (VF), Department of Internal Medicine (MS), and Department of Pediatrics (CM) of the Medical College of Georgia at Augusta University, Augusta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigayle B","family":"Simon","sequence":"additional","affiliation":[{"name":"School of Medicine (CJW, RV, DT, ABS), Department of Pharmacy (VF), Department of Internal Medicine (MS), and Department of Pediatrics (CM) of the Medical College of Georgia at Augusta University, Augusta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Stokes","sequence":"additional","affiliation":[{"name":"School of Medicine (CJW, RV, DT, ABS), Department of Pharmacy (VF), Department of Internal Medicine (MS), and Department of Pediatrics (CM) of the Medical College of Georgia at Augusta University, Augusta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen","family":"McDonough","sequence":"additional","affiliation":[{"name":"School of Medicine (CJW, RV, DT, ABS), Department of Pharmacy (VF), Department of Internal Medicine (MS), and Department of Pediatrics (CM) of the Medical College of Georgia at Augusta University, Augusta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"article-title":"FDA approves dabrafenib with trametinib for pediatric patients with low-grade glioma with a BRAF V600E mutation","year":"2023","key":"i2331-348X-30-4-515-b01","unstructured":"US Food and Drug Administration. FDA approves dabrafenib with trametinib for pediatric patients with low-grade glioma with a BRAF V600E mutation. March 31, 2023. Accessed May 9, 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-dabrafenib-trametinib-pediatric-patients-low-grade-glioma-braf-v600e-mutation"},{"issue":"3","key":"i2331-348X-30-4-515-b02","series-title":"J Clin Oncol","first-page":"664","article-title":"Efficacy and safety of trametinib monotherapy or in combination with dabrafenib in pediatric braf v600\u2013mutant low-grade glioma","volume":"41","author":"Bouffet","year":"2023","unstructured":"Bouffet E, Geoerger B, Moertel C, et al. Efficacy and safety of trametinib monotherapy or in combination with dabrafenib in pediatric braf v600\u2013mutant low-grade glioma. J Clin Oncol. 2023;41(3):664\u2013674."},{"issue":"10","key":"i2331-348X-30-4-515-b03","series-title":"Neuro-Oncol","first-page":"1777","article-title":"A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study","volume":"23","author":"Fangusaro","year":"2021","unstructured":"Fangusaro J, Onar-Thomas A, Poussaint TY, et al. A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study. Neuro-Oncol. 2021;23(10):1777."},{"issue":"7","key":"i2331-348X-30-4-515-b04","series-title":"Lancet Oncol","first-page":"1011","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","unstructured":"Fangusaro J, Onar-Thomas A, Young Poussaint T, et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol. 2019;20(7):1011\u20131022."},{"issue":"36","key":"i2331-348X-30-4-515-b05","series-title":"Proc Natl Acad Sci U S A","first-page":"e2107207118","article-title":"Allosteric MEK inhibitors act on BRAF\/MEK complexes to block MEK activation","volume":"118","author":"Gonzalez-Del Pino","year":"2021","unstructured":"Gonzalez-Del Pino GL, Li K, Park E, Schmoker AM, Ha BH, Eck MJ. Allosteric MEK inhibitors act on BRAF\/MEK complexes to block MEK activation. Proc Natl Acad Sci U S A. 2021;118(36):e2107207118."},{"key":"i2331-348X-30-4-515-b06","series-title":"Pharmacol Res","first-page":"20","article-title":"Allosteric MEK1\/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas","volume":"117","author":"Roskoski","year":"2017","unstructured":"Roskoski R. Allosteric MEK1\/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas. Pharmacol Res. 2017;117:20\u201331."},{"issue":"7466","key":"i2331-348X-30-4-515-b07","series-title":"Nature","first-page":"232","article-title":"Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers","volume":"501","author":"Hatzivassiliou","year":"2013","unstructured":"Hatzivassiliou G, Haling JR, Chen H, et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature. 2013;501(7466):232\u2013236."},{"issue":"2","key":"i2331-348X-30-4-515-b08","series-title":"Proc Natl Acad Sci U S A","first-page":"448","article-title":"Cell cycle arrest mediated by the MEK\/mitogen-activated protein kinase pathway","volume":"94","author":"Pumiglia","year":"1997","unstructured":"Pumiglia KM, Decker SJ. Cell cycle arrest mediated by the MEK\/mitogen-activated protein kinase pathway. Proc Natl Acad Sci U S A. 1997;94(2):448\u2013452."},{"issue":"15_suppl","key":"i2331-348X-30-4-515-b09","series-title":"J Clin Oncol","first-page":"9529","article-title":"A phase 2 clinical trial on trametinib and low-dose dabrafenib in advanced pretreated BRAFV600\/NRASQ61R\/K\/L wild-type melanoma (TraMel-WT): interim efficacy and safety results","volume":"39","author":"Awada","year":"2021","unstructured":"Awada G, Schwarze JK, Tijtgat J, Fasolino G, Everaert H, Neyns B. A phase 2 clinical trial on trametinib and low-dose dabrafenib in advanced pretreated BRAFV600\/NRASQ61R\/K\/L wild-type melanoma (TraMel-WT): interim efficacy and safety results. J Clin Oncol. 2021;39(15_suppl):9529\u20139529."},{"issue":"1","key":"i2331-348X-30-4-515-b10","series-title":"Cancers","first-page":"141","article-title":"BRAF and MEK inhibitors and their toxicities: a meta-analysis","volume":"15","author":"Garutti","year":"2022","unstructured":"Garutti M, Bergnach M, Polesel J, Palmero L, Pizzichetta MA, Puglisi F. BRAF and MEK inhibitors and their toxicities: a meta-analysis. Cancers. 2022;15(1):141."},{"issue":"5","key":"i2331-348X-30-4-515-b11","series-title":"Clin Cancer Res Off J Am Assoc Cancer Res","first-page":"1613","article-title":"The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1\/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer","volume":"16","author":"Banerji","year":"2010","unstructured":"Banerji U, Camidge DR, Verheul HMW, et al. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1\/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2010;16(5):1613\u20131623."},{"issue":"7","key":"i2331-348X-30-4-515-b12","series-title":"The Oncologist","first-page":"e1109","article-title":"The use of MEK Inhibitors in neurofibromatosis type 1-associated tumors and management of toxicities","volume":"25","author":"Klesse","year":"2020","unstructured":"Klesse LJ, Jordan JT, Radtke HB, et al. The use of MEK Inhibitors in neurofibromatosis type 1-associated tumors and management of toxicities. The Oncologist. 2020;25(7):e1109\u2013e1116."},{"issue":"13","key":"i2331-348X-30-4-515-b13","series-title":"J Clin Oncol Off J Am Soc Clin Oncol","first-page":"2139","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1\/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers","volume":"26","author":"Adjei","year":"2008","unstructured":"Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1\/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(13):2139\u20132146."},{"issue":"15","key":"i2331-348X-30-4-515-b14","series-title":"N Engl J Med","first-page":"1430","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","unstructured":"Gross AM, Wolters PL, Dombi E, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020;382(15):1430\u20131442."},{"article-title":"Koselugo\u00ae (selumetinib) [package insert]","year":"2024","key":"i2331-348X-30-4-515-b15","unstructured":"Koselugo\u00ae (selumetinib) [package insert]. Boston, MA: Alexion; 2024. Accessed May 12, 2024. https:\/\/koselugohcp.com\/safety?utm_source=Paid+Search&utm_medium=Google+RSA&utm_campaign=HCP+Branded+New+Site+2024&utm_content=Safety+Ad+Group&gad_source=1&gclid=CjwKCAjw0YGyBhByEiwAQmBEWkJiznuy8fV5E7-KGyaeBy7z6IMlbjsM6KgbYzpihxYrzPtYCzisLRoClG4QAvD_BwE"},{"article-title":"MEKINIST\u00ae [package insert]","year":"2013","key":"i2331-348X-30-4-515-b16","unstructured":"MEKINIST\u00ae [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2013. Accessed September 16, 2024. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/mekinist.pdf"},{"issue":"4","key":"i2331-348X-30-4-515-b17","series-title":"The Oncologist","first-page":"403","article-title":"Low-grade gliomas","volume":"19","author":"Forst","year":"2014","unstructured":"Forst DA, Nahed BV, Loeffler JS, Batchelor TT. Low-grade gliomas. The Oncologist. 2014;19(4):403\u2013413."},{"issue":"6","key":"i2331-348X-30-4-515-b18","series-title":"Acta Neuropathol (Berl)","first-page":"803","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary","volume":"131","author":"Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol (Berl). 2016;131(6):803\u2013820."},{"issue":"2","key":"i2331-348X-30-4-515-b19","series-title":"Asian J Neurosurg","first-page":"356","article-title":"Diffuse low-grade glioma - changing concepts in diagnosis and management: a review","volume":"14","author":"Jooma","year":"2019","unstructured":"Jooma R, Waqas M, Khan I. Diffuse low-grade glioma - changing concepts in diagnosis and management: a review. Asian J Neurosurg. 2019;14(2):356\u2013363."},{"issue":"21","key":"i2331-348X-30-4-515-b20","series-title":"Cancer Res","first-page":"8673","article-title":"Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas","volume":"68","author":"Jones","year":"2008","unstructured":"Jones DTW, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008;68(21):8673\u20138677."},{"issue":"7","key":"i2331-348X-30-4-515-b21","series-title":"J Neuropathol Exp Neurol","first-page":"743","article-title":"KIAA1549: BRAF gene fusion and fgfr1 hotspot mutations are prognostic factors in pilocytic astrocytomas","volume":"74","author":"Becker","year":"2015","unstructured":"Becker AP, Scapulatempo-Neto C, Carloni AC, et al. KIAA1549: BRAF gene fusion and fgfr1 hotspot mutations are prognostic factors in pilocytic astrocytomas. J Neuropathol Exp Neurol. 2015;74(7):743\u2013754."},{"issue":"8","key":"i2331-348X-30-4-515-b22","series-title":"N Engl J Med","first-page":"765","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","unstructured":"Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765\u2013773."},{"issue":"6048","key":"i2331-348X-30-4-515-b23","series-title":"Science","first-page":"1453","article-title":"Mutations in CIC and FUBP1 contribute to human oligodendroglioma","volume":"333","author":"Bettegowda","year":"2011","unstructured":"Bettegowda C, Agrawal N, Jiao Y, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science. 2011;333(6048):1453\u20131455."},{"issue":"9830","key":"i2331-348X-30-4-515-b24","series-title":"Lancet Lond Engl","first-page":"1984","article-title":"Primary brain tumours in adults","volume":"379","author":"Ricard","year":"2012","unstructured":"Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY. Primary brain tumours in adults. Lancet Lond Engl. 2012;379(9830):1984\u20131996."},{"issue":"13","key":"i2331-348X-30-4-515-b25","series-title":"Neurology","first-page":"1366","article-title":"Outcome in adult low-grade glioma: the impact of prognostic factors and treatment","volume":"69","author":"Schiff","year":"2007","unstructured":"Schiff D, Brown PD, Giannini C. Outcome in adult low-grade glioma: the impact of prognostic factors and treatment. Neurology. 2007;69(13):1366\u20131373."},{"issue":"1","key":"i2331-348X-30-4-515-b26","series-title":"Acta Neuropathol (Berl)","first-page":"93","article-title":"Epidemiology and etiology of gliomas","volume":"109","author":"Ohgaki","year":"2005","unstructured":"Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol (Berl). 2005;109(1):93\u2013108."},{"issue":"8","key":"i2331-348X-30-4-515-b27","series-title":"J Clin Oncol Off J Am Soc Clin Oncol","first-page":"1338","article-title":"Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas","volume":"26","author":"Smith","year":"2008","unstructured":"Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(8):1338\u20131345."},{"issue":"4","key":"i2331-348X-30-4-515-b28","series-title":"Neurosurgery","first-page":"753","article-title":"Glioma extent of resection and its impact on patient outcome","volume":"62","author":"Sanai","year":"2008","unstructured":"Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008;62(4):753\u2013764; discussion 264\u2013266."},{"issue":"5","key":"i2331-348X-30-4-515-b29","series-title":"J Clin Oncol Off J Am Soc Clin Oncol","first-page":"850","article-title":"Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood","volume":"11","author":"Packer","year":"1993","unstructured":"Packer RJ, Lange B, Ater J, et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol Off J Am Soc Clin Oncol. 1993;11(5):850\u2013856."},{"issue":"5","key":"i2331-348X-30-4-515-b30","series-title":"J Neurosurg","first-page":"747","article-title":"Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas","volume":"86","author":"Packer","year":"1997","unstructured":"Packer RJ, Ater J, Allen J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg. 1997;86(5):747\u2013754."},{"issue":"25","key":"i2331-348X-30-4-515-b31","series-title":"J Clin Oncol Off J Am Soc Clin Oncol","first-page":"2934","article-title":"Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas","volume":"35","author":"Lassaletta","year":"2017","unstructured":"Lassaletta A, Zapotocky M, Mistry M, et al. Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(25):2934\u20132941."},{"issue":"9","key":"i2331-348X-30-4-515-b32","series-title":"J Clin Oncol Off J Am Soc Clin Oncol","first-page":"1015","article-title":"BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma","volume":"33","author":"Mistry","year":"2015","unstructured":"Mistry M, Zhukova N, Merico D, et al. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(9):1015\u20131022."},{"key":"i2331-348X-30-4-515-b33","series-title":"Side Effects of Drugs Annual","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/bs.seda.2022.08.006","article-title":"Side effects of anti-cancer medications","author":"Zhong","year":"2022","unstructured":"Zhong Q, Zee K, Rasmussen K, et al. Side effects of anti-cancer medications. In: Ray SD, ed. Side Effects of Drugs Annual. Vol 44: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. Amsterdam, the Netherlands: Elsevier; 2022:431\u2013445."},{"issue":"2","key":"i2331-348X-30-4-515-b34","series-title":"Ther Adv Drug Saf","first-page":"61","article-title":"Adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital","volume":"8","author":"Wahlang","year":"2017","unstructured":"Wahlang JB, Laishram PD, Brahma DK, et al. Adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital. Ther Adv Drug Saf. 2017;8(2):61\u201366."},{"article-title":"Adverse drug reaction probability scale (Naranjo) in drug induced liver injury","year":"2012","key":"i2331-348X-30-4-515-b35","unstructured":"National Library of Medicine. Adverse drug reaction probability scale (Naranjo) in drug induced liver injury. 2012. Accessed June 3, 2024. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548069\/"},{"issue":"2","key":"i2331-348X-30-4-515-b36","series-title":"Clin Pharmacol Ther","first-page":"239","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u2013245."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/30\/4\/article-p515.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/30\/4\/article-p515.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/30\/4\/article-p515.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T19:46:14Z","timestamp":1755114374000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/30\/4\/article-p515.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":36,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.5863\/jppt-24-00002","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"type":"electronic","value":"2331-348X"},{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}